These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
973 related articles for article (PubMed ID: 27255713)
21. Direct oral anticoagulants in the treatment of acute venous thromboembolism: a systematic review and meta-analysis. Gómez-Outes A; Terleira-Fernández AI; Lecumberri R; Suárez-Gea ML; Vargas-Castrillón E Thromb Res; 2014 Oct; 134(4):774-82. PubMed ID: 25037495 [TBL] [Abstract][Full Text] [Related]
22. Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis. Cohen AT; Hamilton M; Mitchell SA; Phatak H; Liu X; Bird A; Tushabe D; Batson S PLoS One; 2015; 10(12):e0144856. PubMed ID: 26716830 [TBL] [Abstract][Full Text] [Related]
23. Anticoagulants: What is new and what is the standard? Lesko LJ Clin Pharmacol Ther; 2016 Aug; 100(2):126-8. PubMed ID: 27197625 [TBL] [Abstract][Full Text] [Related]
24. Antidotes to non-vitamin K oral anticoagulants: necessary or not? Proietti M; Lip GY Expert Opin Pharmacother; 2015; 16(11):1573-6. PubMed ID: 26077323 [TBL] [Abstract][Full Text] [Related]
25. Direct Oral Anticoagulants for the Treatment of Venous Thromboembolism in Japan. Nakamura M; Yamada N; Ito M J Atheroscler Thromb; 2017 Jun; 24(6):560-565. PubMed ID: 28392512 [TBL] [Abstract][Full Text] [Related]
26. Safety ad efficacy of direct oral anticoagulants for extended treatment of venous thromboembolism. Imberti D; Pomero F; Benedetti R; Fenoglio L Intern Emerg Med; 2016 Oct; 11(7):895-900. PubMed ID: 27550399 [TBL] [Abstract][Full Text] [Related]
27. A systematic review and Bayesian network meta-analysis of risk of intracranial hemorrhage with direct oral anticoagulants. Wolfe Z; Khan SU; Nasir F; Raghu Subramanian C; Lash B J Thromb Haemost; 2018 Jul; 16(7):1296-1306. PubMed ID: 29723935 [TBL] [Abstract][Full Text] [Related]
28. [Non-vitamin K dependent oral anticoagulants : What is important in intensive care medicine]. Gulba DC; Broscaru L Med Klin Intensivmed Notfmed; 2017 Mar; 112(2):83-91. PubMed ID: 28144727 [TBL] [Abstract][Full Text] [Related]
29. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. Nielsen PB; Skjøth F; Søgaard M; Kjældgaard JN; Lip GY; Larsen TB BMJ; 2017 Feb; 356():j510. PubMed ID: 28188243 [No Abstract] [Full Text] [Related]
30. Is it reasonable to use a lower DOACs dose in some patients with VTE? Yes. Imberti D; Mastroiacovo D Intern Emerg Med; 2017 Aug; 12(5):561-563. PubMed ID: 28647891 [TBL] [Abstract][Full Text] [Related]
31. Minimizing the Risk of Bleeding with NOACs in the Elderly. Kundu A; Sardar P; Chatterjee S; Aronow WS; Owan T; Ryan JJ Drugs Aging; 2016 Jul; 33(7):491-500. PubMed ID: 27174293 [TBL] [Abstract][Full Text] [Related]
32. Bleeding risk of apixaban, dabigatran, and low-dose rivaroxaban compared with warfarin in Japanese patients with non-valvular atrial fibrillation: a propensity matched analysis of administrative claims data. Kohsaka S; Murata T; Izumi N; Katada J; Wang F; Terayama Y Curr Med Res Opin; 2017 Nov; 33(11):1955-1963. PubMed ID: 28857611 [TBL] [Abstract][Full Text] [Related]
33. Hospital length of stay in patients initiated on direct oral anticoagulants versus warfarin for venous thromboembolism: a real-world single-center study. Badreldin H J Thromb Thrombolysis; 2018 Jul; 46(1):16-21. PubMed ID: 29626281 [TBL] [Abstract][Full Text] [Related]
34. [State of the art: Direct oral anticoagulants and transfusion]. Martin AC; Godier A; Smadja DM; Mauge L; Fischer AM Transfus Clin Biol; 2017 Sep; 24(3):154-159. PubMed ID: 28673500 [TBL] [Abstract][Full Text] [Related]
35. [Factors Associated with Direct Oral Anticoagulants versus Vitamin K Antagonists in Patients with Non-valvular Atrial Fibrillation]. Saliba L; Mondoly P; Duparc A; Bura-Rivière A; Maury P; Calmels V; Sallerin B; Pathak A; Montastruc JL; Bagheri H Therapie; 2015; 70(6):485-92. PubMed ID: 26223162 [TBL] [Abstract][Full Text] [Related]
36. Comparison of the Non-VKA Oral Anticoagulants Apixaban, Dabigatran, and Rivaroxaban in the Extended Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis. Cohen AT; Hamilton M; Bird A; Mitchell SA; Li S; Horblyuk R; Batson S PLoS One; 2016; 11(8):e0160064. PubMed ID: 27487187 [TBL] [Abstract][Full Text] [Related]
37. [Analysis of the Risk Factors Associated with Minor Bleeding in Patients with Venous Thromboembolism during Treatment with Direct Oral Anticoagulants]. Sunaga T; Shimizu T; Nakamura S; Takahashi N; Higashino M; Matsui M; Hozumi T; Ebato M; Suzuki H; Kogo M; Watanabe T; Sasaki T Yakugaku Zasshi; 2019; 139(3):461-467. PubMed ID: 30828024 [TBL] [Abstract][Full Text] [Related]
38. Evaluation of Dose-Reduced Direct Oral Anticoagulant Therapy. Barra ME; Fanikos J; Connors JM; Sylvester KW; Piazza G; Goldhaber SZ Am J Med; 2016 Nov; 129(11):1198-1204. PubMed ID: 27341955 [TBL] [Abstract][Full Text] [Related]
39. Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of pulmonary embolism. Robertson L; Kesteven P; McCaslin JE Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD010957. PubMed ID: 26636644 [TBL] [Abstract][Full Text] [Related]
40. Comparison of direct oral anticoagulants and warfarin in chronic limb-threatening ischemia. Rockhold M; Kunkel L; Lacoste JL; Szymanski T; Rothenberg P; Zimmerman P; Minc S J Vasc Surg; 2024 Jun; 79(6):1466-1472.e1. PubMed ID: 38278371 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]